| Added by | mollevi |
|---|---|
| Last modified by | celine.gongora |
| Group name | EquipeCG |
| Item Type | Journal Article |
| Title | Enterocolitis in Patients with Cancer Treated with Docetaxel |
| Creator | Fiteni et al. |
| Author | Marie-Justine Paillard |
| Author | Emeline Orillard |
| Author | Loriane Lefebvre |
| Author | Sarah Nadjafizadeh |
| Author | Zohair Selmani |
| Author | Salim Benhamida |
| Author | Antoine Roland |
| Author | Antoine Baumann |
| Author | Angélique Vienot |
| Author | Nadine Houédé |
| Author | Xavier Pivot |
| Abstract | BACKGROUND: Enterocolitis is a rare, but serious gastrointestinal complication associated with docetaxel-based chemotherapy in patients with cancer. The incidence, clinical presentation and outcome of enterocolitis in patients with cancer treated with docetaxel-based chemotherapy was assessed in this study Patients and Methods: All patients treated with docetaxel for cancer between January 2010 and December 2014 at the University Hospital of Besançon were identified and their medical records reviewed. RESULTS: During this period, 1,227 patients received docetaxel chemotherapy and gastrointestinal events occurred in 381 (31.1%) patients. In multivariate analysis, a higher risk of gastrointestinal events was associated with a higher dose of docetaxel (?75 mg/m2) (odds ratio(OR)=46.2; 95% confidence interval(CI)=5.4-397.0, p=0.0005) and the first cycle of docetaxel (OR=4.2; 95% CI=1.8-10.1, p=0.001). Among the 381 patients with gastrointestinal events, grade 3/4 neutropenia, diarrhea, febrile neutropenia, mucositis, nausea/vomiting, and rectal bleeding were diagnosed in 65 (17.1%), 51 (13.4%), 37 (9.7%); 12 (3.1%), seven (1.8%) and three (0.8%) patients, respectively; 54 patients (14.2%) were hospitalized. Computed tomographic scan was performed for 39 patients (10.2%). Twenty-seven patients presented radiological signs of enterocolitis. Three deaths (0.8%) related to enterocolitis were recorded. Docetaxel was resumed in 261 patients (68.5%) and the dose was reduced in 89 patients (23.4%). Docetaxel was discontinued in 120 patients (31.5%). CONCLUSION: Gastrointestinal events in patients treated with docetaxel may be a potential sign of fatal enterocolitis and require particular attention. Dose reduction at the first cycle may reduce the risk of such events. |
| Publication | Anticancer Research |
| Volume | 38 |
| Issue | 4 |
| Pages | 2443-2446 |
| Date | 04 2018 |
| Journal Abbr | Anticancer Res. |
| Language | eng |
| DOI | 10.21873/anticanres.12497 |
| ISSN | 1791-7530 |
| Library Catalog | PubMed |
| Extra | PMID: 29599375 |
| Tags | Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, cancer, clinic, Dose-Response Relationship, Drug, Enterocolitis, Female, Humans, Incidence, Male, Middle Aged, Nausea, Neoplasms, Neutropenia, Retrospective Studies, Taxoids, typhlitis, Vomiting, Young Adult |
| Date Added | 2018/09/14 - 16:39:23 |
| Date Modified | 2019/05/14 - 13:25:20 |
Institut de Recherche en Cancérologie de
